Evidence map›Paper›PMID 38365735›Full record

SynthesisSystematic reviews2024

The global economic burden of COVID-19 disease: a comprehensive systematic review and meta-analysis.

Ahmad Faramarzi, Soheila Norouzi, Hossein Dehdarirad, Siamak Aghlmand, Hasan Yusefzadeh, Javad Javan-Noughabi

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Systematic reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Zirconium-based metal-organic frameworks for pathogen detection.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ahmad FaramarziDepartment of Health Economics and Management, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran. ahmadfaramarzi97@yahoo.com.ORCID 0000-0001-5661-8991
Soheila NorouziDepartment of Health Economics and Management, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran.ORCID 0000-0002-3028-7861
Hossein DehdariradDepartment of Medical Library and Information Science, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Siamak AghlmandDepartment of Health Economics and Management, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran.
Hasan YusefzadehDepartment of Health Economics and Management, School of Public Health, Urmia University of Medical Sciences, Urmia, Iran.
Javad Javan-NoughabiSocial Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Urmia University · IRMashhad University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has caused a considerable threat to the economics of patients, health systems, and society.

objectivesThis meta-analysis aims to quantitatively assess the global economic burden of COVID-19.

methodsA comprehensive search was performed in the PubMed, Scopus, and Web of Science databases to identify studies examining the economic impact of COVID-19. The selected studies were classified into two categories based on the cost-of-illness (COI) study approach: top-down and bottom-up studies. The results of top-down COI studies were presented by calculating the average costs as a percentage of gross domestic product (GDP) and health expenditures. Conversely, the findings of bottom-up studies were analyzed through meta-analysis using the standardized mean difference.

resultsThe implemented search strategy yielded 3271 records, of which 27 studies met the inclusion criteria, consisting of 7 top-down and 20 bottom-up studies. The included studies were conducted in various countries, including the USA (5), China (5), Spain (2), Brazil (2), South Korea (2), India (2), and one study each in Italy, South Africa, the Philippines, Greece, Iran, Kenya, Nigeria, and the Kingdom of Saudi Arabia. The results of the top-down studies indicated that indirect costs represent 10.53% of GDP, while the total estimated cost accounts for 85.91% of healthcare expenditures and 9.13% of GDP. In contrast, the bottom-up studies revealed that the average direct medical costs ranged from US $1264 to US $79,315. The meta-analysis demonstrated that the medical costs for COVID-19 patients in the intensive care unit (ICU) were approximately twice as high as those for patients in general wards, with a range from 0.05 to 3.48 times higher.

conclusionsOur study indicates that the COVID-19 pandemic has imposed a significant economic burden worldwide, with varying degrees of impact across countries. The findings of our study, along with those of other research, underscore the vital role of economic consequences in the post-COVID-19 era for communities and families. Therefore, policymakers and health administrators should prioritize economic programs and accord them heightened attention.

Indexed as

Cost of IllnessCOVID-19Global HealthSARS-CoV-2Gross Domestic ProductHealth Care CostsHealth ExpendituresHumansPandemicsCost of illnessCOVID-19EconomicsPandemicsSystematic review

Identifiers

PMID38365735
PMCPMC10870589
OpenAlexW4391879807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.